# OnCo record nct04680052 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04680052/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04680052", "NCT04680052" ;
  schema:name "A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Pa"@en ;
  schema:alternateName "InMIND"@en, "inMIND"@en, "Tafasitamab with lenalidomide and rituximab in relapsed or refractory follicular lymphoma"@en ;
  schema:description "A phase 3 trial of Tafasitamab, Rituximab, Lenalidomide in follicular lymphoma, run by Incyte Corporation, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04680052/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04680052> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2021-04-15" ;
  onco:related <https://onco.cc/roadmaps/lymphoma-roadmap/>, <https://onco.cc/key-papers/paper-inmind-tafasitamab-lenalidomide-rituximab-follicular-lancet-2026/>, <https://onco.cc/trials/rosewood/> ;
  onco:cancers <https://onco.cc/cancers/follicular-lymphoma/>, <https://onco.cc/cancers/marginal-zone-lymphoma/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/protac-degrader/> ;
  onco:targets <https://onco.cc/targets/cd19/>, <https://onco.cc/targets/cd20/> ;
  onco:drugs <https://onco.cc/drugs/tafasitamab/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/lenalidomide/> ;
  onco:companies <https://onco.cc/companies/incyte/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-inmind-tafasitamab-lenalidomide-rituximab-follicular-lancet-2026/> .